Driven by prescription drug prices and oft-repeated claims that nearly every drug developed in the U.S. owes its origins to taxpayer-funded research, watchdog groups and some lawmakers have led ...

Infectious disease-focused biopharma companies continued their rebound into year-end, with the BioWorld Infectious Disease Index finishing 2025 up 68.55% after standing at a collective 28.98% at the ...

Medtronic plc this week reported that the first commercial surgical cases using its Hugo robotic-assisted surgery system have been completed in the U.S. Hugo is expected to be a key growth driver for ...

At a time of global transition for life sciences, with China stepping up the pace of innovation and the U.S. adopting protectionist policies, the health innovation region in Catalonia, Spain, is ...

CSL Ltd. is out-licensing its interleukin-6 (IL-6) monoclonal antibody, clazakizumab, to Eli Lilly and Co. in a deal that brings CSL $100 million in up-front fees. A CSL spokesperson told BioWorld the ...

SLAMF6 is an immune cell receptor whose function was not clear. Does it activate or inhibit cells? The results so far have been contradictory. Now, scientists at the Institut de Recherches Cliniques ...

Chronic migraine is a neurological disorder characterized by recurrent headache episodes. Recent findings have implicated microglia in the trigeminal nucleus caudalis in chronic migraine-related ...

Shanghai SIMR Biotech Co. Ltd. has prepared and tested new GABA-A receptor subunit α5 (GABRA5) inverse agonists. They are reported to be useful for the treatment of pain, stroke and Alzheimer’s ...

Researchers from University College London and collaborating institutions have recently published results from their study aiming to optimize gene therapy for CLN5 disease.

Tarapeutics Science Inc. has reported new pyrazolopyridine compounds acting as dual specificity protein kinase CLK and dual specificity tyrosine-phosphorylation-regulated kinase (DYRK) inhibitors.

Mutations in GTPase KRAS, concretely KRAS G12D, are predominant in pancreatic and colorectal cancers and targeting them is still a challenge. Researchers have published results from studies of a new ...

Nonprofit Finding Hope for Frizzle (FRRS1L) and Apertura Gene Therapy have signed a license agreement for the development of a gene therapy for FRRS1L disease, also known as early infantile epileptic ...